[Investigation of therapeutic and protective effect of Reaferon-ES Lipint on mice infected with avian influenza virus (subtype H5N1)].

Abstract

The efficacy of the therapeutic, prophylactic and urgent prophylactic schemes for the use of Reaferon-ES lipint, a liposomal human recombinant alpha-interferon for oral use, was studied on mice infected with the avian influenza virus. Strain A/Chicken/Kurgan /05/2005 (subtype H5N1) of the avian influenza virus showed high virulence with respect to mice ICR. Theoretically-based calculations allowed to design an optimal therapeutic and prophylactic dose of the drug for the mice (1000 units/animal). It was observed that only after prophylactic use of Reaferon-ES lipint it was effective in protection of the mice infected with 10 LD50 of the avian influenza virus (A/Chicken/Kurgan/05/2005, H5N1). The protection coefficient was 0.35. Under such conditions the drug efficacy was comparable with that of Tamiflu. Therefore, Reaferon-ES lipint could be recommended for prophylaxis of the infection due not only to the season strains of the influenza virus, but also to the strains of the avian influenza virus.

• Authors: O K Demina, A A Sergeev, A P Agafonov, A N Shikov, A O Sementsova, A A Sergeev, A N Sergeev, I G Drozdov
• Journal: Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] (Antibiot Khimioter) Vol. 54 Issue 9-10 Pg. 27-9 ( 2009) ISSN: 0235-2990 [Print] Russia (Federation)
• PMID: 20415260 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• Interferon Type I
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins

Topics

• Animals
• Antiviral Agents (therapeutic use)
• Female
• Humans
• Influenza A Virus, H5N1 Subtype (pathogenicity)
• Interferon Type I (therapeutic use)
• Interferon alpha-2
• Interferon-alpha
• Male
• Mice
• Mice, Inbred ICR
• Orthomyxoviridae Infections (drug therapy, prevention & control, virology)
• Recombinant Proteins